CE1 A Modeled Health Outcomes Evaluation of Darolutamide Plus Androgen Deprivation Therapy for High-Risk NON-Metastatic Castration-Resistant Prostate Cancer in China

03 medical and health sciences 0302 clinical medicine
DOI: 10.1016/j.jval.2021.04.011 Publication Date: 2021-06-04T18:43:33Z